Paper Details

  1. Home
  2. Paper Details

Bitopertin in Negative Symptoms of Schizophrenia-Results From the Phase III FlashLyte and DayLyte Studies.

Author: ArangoCelso, BlaettlerThomas, BressanRodrigo A, Bugarski-KirolaDragana, DixonMark, FleischhackerWolfgang W, GaribaldiGeorge, LawrieStephen, MarderStephen R, NapieralskiJulie, NasrallahHenry, Ochi-LohmannTania, ReidCarol, WangAlice

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Three phase III studies evaluating the efficacy of adjunctive bitopertin in patients with persistent predominant negative symptoms of schizophrenia showed no evidence for superior efficacy over placebo in any of the doses tested. Bitopertin was well tolerated.
Paper Details　
Original Abstract of the Article :
BACKGROUND: There is currently no standard of care for treatment of negative symptoms of schizophrenia, although some previous results with glutamatergic agonists have been promising. METHODS: Three (SunLyte [WN25308], DayLyte [WN25309], and FlashLyte [NN25310]) phase III, multicenter, randomized, ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.biopsych.2016.11.014

データ提供：米国国立医学図書館（NLM）

Treating Negative Symptoms of Schizophrenia: A Search for Solutions in the Desert

The desert of schizophrenia is a challenging landscape, with patients facing a variety of debilitating symptoms. This study focuses on negative symptoms, a particularly challenging aspect of the condition, and explores the potential of bitopertin as a treatment option. The researchers conducted three phase III, multicenter, randomized, double-blind, placebo-controlled studies, a method as rigorous as a well-planned caravan expedition, to evaluate the efficacy and safety of bitopertin in patients with persistent predominant negative symptoms of schizophrenia.

Bitopertin: A Potential Oasis in the Desert of Schizophrenia Treatment

The studies' findings, however, did not demonstrate statistically significant improvement in negative symptoms with bitopertin compared to placebo. This outcome is like encountering a mirage in the desert, a fleeting hope that ultimately fades away. The researchers concluded that bitopertin, in the doses tested, did not show superior efficacy over placebo in treating negative symptoms of schizophrenia. This finding underscores the need for continued research and exploration of alternative therapeutic approaches.

Navigating the Desert of Schizophrenia Treatment: A Journey of Hope and Perseverance

The study emphasizes the importance of ongoing research in the field of schizophrenia treatment. It's a reminder that navigating the desert of this complex mental health condition requires a commitment to innovation, a spirit of hope, and unwavering perseverance.

Dr.Camel's Conclusion

The desert of schizophrenia treatment continues to be a challenging landscape. This study, while not yielding positive results for bitopertin, underscores the ongoing need for research and exploration of new therapeutic approaches. We must continue to seek oases of hope and effective solutions for those struggling with this debilitating condition.

Date :
  1. Date Completed 2018-03-09
  2. Date Revised 2018-03-28
Further Info :

Pubmed ID

28117049

DOI: Digital Object Identifier

10.1016/j.biopsych.2016.11.014

Related Literature

Article Analysis
・Effective treatment of schizophrenia
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.